Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: Hypothesis and significance

Journal of Pineal Research

Volumn 43, Issue 4, 2007, Pages 317-320

  Tan, Dun Xian ^a   Manchester, Lucien C ^a,b   Terron, M Pilar ^a   Flores, Luis J ^a   Tamura, Hiroshi ^a   Reiter, Russel J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b ST MARY'S UNIVERSITY   (United States)

Author keywords

Antioxidant; Melatonin; Melatoninergic receptor; MT3; Quinone reductase 2

Indexed keywords

FLAVINE NUCLEOTIDE; MELATONIN; MELATONIN 2 RECEPTOR; MELATONIN 3 RECEPTOR; MEMBRANE RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; DETOXIFICATION; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; NONHUMAN; PROTEIN BINDING; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIOXIDANTS; BINDING SITES; HUMANS; MELATONIN; MODELS, BIOLOGICAL; NAD(P)H DEHYDROGENASE (QUINONE); RECEPTORS, MELATONIN;

EID: 34848928810     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2007.00513.x     Document Type: Short Survey

References (23)

1. Hardeland R, Balzer I, Poeggeler B et al. On the primary functions of melatonin in evolution: mediation of photoperiodic signals in a unicell, photooxidation, and scavenging of free radicals. J Pineal Res 1995 18 : 104 111.
2. Manchester LC, Poeggeler B, Alvares FL, Ogden GB, Reiter RJ. Melatonin immunoreactivity in the photosynthetic prokaryote Rhodospirillum rubrum: implications for an ancient antioxidant system. Cell Mol Biol Res 1995 41 : 391 395.
3. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007 42 : 28 42.
4. Navara KJ, Nelson RJ. The dark side of light at night: physiological, epidemiological, and ecological consequences. J Pineal Res 2007 43 : 215 24.
5. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005 27 : 101 110.
6. Pickering DS, Niles LP. Pharmacological characterization of melatonin binding sites in Syrian hamster hypothalamus. Eur J Pharmacol 1990 175 : 71 77.
7. Pintor J, Martin L, Pelaez T, Hoyle CH, Peral A. Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits. Eur J Pharmacol 2001 416 : 251 254.
8. Serle JB, Wang RF, Peterson WM, Plourde R, Yerxa BR. Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes. J Glaucoma 2004 13 : 385 388.
9. Nosjean O, Ferro M, Coge F et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000 275 : 31311 31317.
10. Mailliet F, Ferry G, Vella F et al. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem Pharmacol 2005 71 : 74 88.
11. Mailliet F, Ferry G, Vella F, Thiam K, Delagrange P, Boutin JA. Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett 2004 578 : 116 120.
12. Nosjean O, Nicolas JP, Klupsch F, Delagrange P, Canet E, Boutin JA. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem Pharmacol 2001 61 : 1369 1379.
13. Liao S, Williams-Ashman HG. Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide. Biochem Biophys Res Commun 1961 4 : 208 213.
14. Vella F, Ferry G, Delagrange P, Boutin JA. NRH:Quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol 2005 71 : 1 12.
15. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. A potent endogenous hydroxyl radical scavenger. Endocr J 1993 1 : 57 60.
16. Reiter RJ, Tan DX, Manchester LC, Lopez-Burillo S, Sainz RM, Mayo JC. Melatonin: detoxification of oxygen and nitrogen-based toxic reactants. Adv Exp Med Biol 2003 527 : 539 548.
17. Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005 27 : 119 130.
18. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991 12 : 151 180.
19. Tutuncu NB, Batur MK, Yildirir A et al. Melatonin levels decrease in type 2 diabetic patients with cardiac autonomic neuropathy. J Pineal Res 2005 39 : 43 49.
20. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res 2005 38 : 145 152.
21. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res 2007 42 : 319 322.
22. Tan DX, Manchester LC, Sainz R, Mayo JC, Alvares FL, Reiter RJ. Antioxidant strategies in protection against neurodegenerative disorders. Expert Opin Ther Pat 2003 13 : 1513 1543.
23. Yaprak M, Altun A, Vardar A, Aktoz M, Ciftci S, Ozbay G. Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. Int J Cardiol 2003 89 : 103 107.